ADCC Bioassay Effector Cell F Variant (Low Affinity)/ NFAT Luciferase Reporter Jurkat Cell Line is an engineered Jurkat T cell line expressing firefly luciferase under the control of NFAT response elements, and human FcγRIIIa low affinity (F158) variant and Fcγ chain. This cell line was functionally validated by ADCC (antibody-dependent cell-mediated cytotoxicity) assays.

Figure 1: Illustration of the mechanism of action of ADCC Bioassay Effector Cell F Variant (Low Affinity)/NFAT Luciferase Reporter Jurkat Cell Line.
ADCC Bioassay Effector Cell F Variant (Low Affinity)/NFAT Luciferase Reporter Jurkat cells are used as effector cells. The effector cells are co-cultured in the presence of target cells and an antibody of interest. The antibody binds to the target antigen on the target cell whereas its Fc portion binds to FcγRIIIa on the cell surface of the effector cell, cross-linking the effector and target cells. Engagement of FcγRIIIa leads to the activation of the NFAT pathway in the effector cells. Luciferase activity is proportional to the activation of the ADCC cascade.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.